Host cells subdivide nutrient niches into discrete biogeographical microhabitats for gut microbes

Liou, Megan J.; Miller, Brittany; Litvak, Yael; Nguyen, Henry; Natwick, Dean E.; Savage, Hannah P; Rixon, Jordan; Mahan, Scott; Hiyoshi, Hirotaka; Rogers, Alisdair; Velazquez, Eric M.; Butler, Brian P.; Collins, Sean R.; McSorley, Stephen J.; Harshey, Rasika M.; Byndloss, Mariana X.; Simon, Scott I.; Bäumler, Andreas J.

doi:10.1016/j.chom.2022.04.012

Cited by 33 publications

(25 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As anticipated, the probiotic induced no significant alterations in the global gut microbiome community composition of the human participants (25). This agrees with prior literature that demonstrates a limited long-term alteration in the gut microbiota from probiotics in healthy adults, that stems from colonization resistance from the microbiota and host factors that perform ecology maintenance (25-29). We speculate that the ASV aligned to Lactobacillus murinius is a miss-identified detection of our probiotic stains, an assertion that is supported by our detection and identification of the probiotic strains by qPCR and the rarity of this strain as a human commensal.…”

Section: Discussionsupporting

confidence: 92%

Clinical Trial of a Probiotic and Herbal Supplement for Lung and Gut Health

Wenger

Qiao

Nicola

et al. 2023

Preprint

View full text Add to dashboard Cite

Rationale: Dysbiosis of the gut microbiome may augment lung disease via the gut-lung axis. Proteobacteria may increase MMP-9 release and contribute to tissue proteolysis followed by neutrophil recruitment, lung tissue injury, and perpetuation of chronic lung disease. Trial Design: We sought to determine if a probiotic and herbal blend was safe and well-tolerated in healthy volunteers and asthmatic patients. Methods: We conducted a 1-month randomized, open-label clinical trial in Cork, Ireland with healthy and asthmatic patients who took the blend twice a day. The primary endpoint was safety with secondary endpoints including quality of life, lung function, gut microbiome ecology, and inflammatory biomarkers. Results: All subjects tolerated the blend without adverse events. Asthmatic subjects who took the blend showed significant improvements in lung function and serum short chain fatty acid levels from baseline to Week 4. The gut microbiome of asthmatic subjects differed significantly from controls, with the most prominent difference in the relative abundance of the proteobacteria Escherichia coli. Administration of the probiotic maintained overall microbial community architecture with the only significant difference being an increase in absolute abundance of the probiotic strains measured by strain-specific PCR. Conclusions: This study supports the safety and efficacy potential of oral probiotic administration of the probiotic and herbal to act on the gut-lung axis.

show abstract

Section: Discussionsupporting

confidence: 92%

Clinical Trial of a Probiotic and Herbal Supplement for Lung and Gut Health

Wenger

Qiao

Nicola

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Tm from the diseased gut. 30 , 44 , 99 , 100 Competition for micronutrients, such as iron ions, terminal electron acceptors like oxygen or nitrate and bacteriocin production, is thought to contribute to this E. coli -mediated CR against Salmonella infection. 30 , 78 , 101 , 102 …”

Section: Mouse Models For Enteropathogen Infectionmentioning

confidence: 99%

Mouse models for bacterial enteropathogen infections: insights into the role of colonization resistance

et al. 2023

View full text Add to dashboard Cite

Globally, enteropathogenic bacteria are a major cause of morbidity and mortality. 1-3 Campylobacter, Salmonella , Shiga-toxin-producing Escherichia coli , and Listeria are among the top five most commonly reported zoonotic pathogens in the European Union. 4 However, not all individuals naturally exposed to enteropathogens go on to develop disease. This protection is attributable to colonization resistance (CR) conferred by the gut microbiota, as well as an array of physical, chemical, and immunological barriers that limit infection. Despite their importance for human health, a detailed understanding of gastrointestinal barriers to infection is lacking, and further research is required to investigate the mechanisms that underpin inter-individual differences in resistance to gastrointestinal infection. Here, we discuss the current mouse models available to study infections by non-typhoidal Salmonella strains, Citrobacter rodentium (as a model for enteropathogenic and enterohemorrhagic E. coli), Listeria monocytogenes , and Campylobacter jejuni. Clostridioides difficile is included as another important cause of enteric disease in which resistance is dependent upon CR. We outline which parameters of human infection are recapitulated in these mouse models, including the impact of CR, disease pathology, disease progression, and mucosal immune response. This will showcase common virulence strategies, highlight mechanistic differences, and help researchers from microbiology, infectiology, microbiome research, and mucosal immunology to select the optimal mouse model.

show abstract

“…coli are able to compete with S . Typhimurium for nitrate to restrict its growth [96]. In a mouse model, probiotic E.…”

Section: Introductionmentioning

confidence: 99%

Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization

et al. 2023

View full text Add to dashboard Cite

The human gut microbiota can restrict the growth of pathogens to prevent them from colonizing the intestine (‘colonization resistance’). However, antibiotic treatment can kill members of the gut microbiota (‘gut commensals’) and reduce competition for nutrients, making these nutrients available to support the growth of pathogens. This disturbance can lead to the growth and expansion of pathogens within the intestine (including antibiotic-resistant pathogens), where these pathogens can exploit the absence of competitors and the nutrient-enriched gut environment. In this review, we discuss nutrient competition between the gut microbiota and pathogens. We also provide an overview of how nutrient competition can be harnessed to support the design of next-generation microbiome therapeutics to restrict the growth of pathogens and prevent the development of invasive infections.

show abstract

Host cells subdivide nutrient niches into discrete biogeographical microhabitats for gut microbes

Cited by 33 publications

References 66 publications

Clinical Trial of a Probiotic and Herbal Supplement for Lung and Gut Health

Clinical Trial of a Probiotic and Herbal Supplement for Lung and Gut Health

Mouse models for bacterial enteropathogen infections: insights into the role of colonization resistance

Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization

Contact Info

Product

Resources

About